Park H, Kang DY, Kim SO, et al. - Extended follow-up of patients who had drug-eluting stents implantation revealed high overall adverse clinical event rates (with a linearly increasing event rate over time). Sirolimus-eluting stents (SES) vs paclitaxel-eluting stents (PES) for left main coronary artery (LMCA) disease showed no measurable differences in outcomes at 10 years.

• Ten-year extended follow-up of the MAINCOMPARE registry was performed.

• Participants were 778 patients with unprotected LMCA stenosis who were managed with SES (n = 607) or PES (n = 171).

• A composite of death, myocardial infarction or target-vessel revascularization was the primary composite outcome.

• Inverse-probability-of-treatment-weighting -adjusted analyses revealed that the risks for the primary composite outcome or definite stent thrombosis did not differ significantly between SES and PES.

• Stent thrombosis incidence was quite low and comparable between the groups.